Pfizer and Astellas announce results from phase 3 EV-302 clinical trial
Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and ...
Pfizer and Astellas report improved survival in bladder cancer trial
NEW YORK & TOKYO - Pfizer Inc. (NYSE: NYSE:PFE) and Astellas Pharma Inc. (TSE: TYO:4503) have announced updated results from the Phase 3 EV-302 clinical trial, which showed that the combination of ...
FiercePharma5d
Astellas takes $760M charge, reveals slowdown for eye drug Izervay after regulatory stumbles
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...
Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit
Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...
Hosted on MSN15d
Astellas Exec Talks Dealmaking and Pipeline Strategy in Cancer, Gene Therapy & More
The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.
FierceBiotech7d
Astellas fires CSO and chief manufacturing officer in C-suite shake-up
Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of chief ...
GlobalData on MSN5d
Astellas seeks conditional approval for GA treatment in Japan
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Antibiotics Market Expected To Reach USD 72.9 Billion by 2032, Growing at CAGR 4.1% | Abbott Laboratories, Astellas Pharma, Bayer
The FDA announced the approval of a new treatment for pneumonia caused by certain difficult-to-treat bacteria, offering hope ...
The Pharma Letter5d
Astellas changes management structure
Not satisfied with simply changing personnel, Japanese drugmaker Astellas has announced a new management structure, effective ...
MM&M5d
The Escalator: Astellas Pharma, Moderna, Minds + Assembly and more
Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...
Astellas Pharma Submits NDA For Avacincaptad Pegol For Geographic Atrophy In Japan
(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP for ...